Hepatology Resource Center
DAAs dramatically increase HCV cure rates among veterans April 14, 2017By Mark FuerstThe introduction of direct-acting antiviral agents has transformed hepatitis C care among veterans. Multiple DAAs provide quality care for HCV patients April 14, 2017By Mark FuerstMultiple oral direct-acting antiviral agents show great promise in treating the vast majority of hepatitis C patients. Real-world DAA therapy shows gains in community setting March 17, 2017By Mark L. FuerstPhysicians have a “good, effective, safe therapy available” for hepatitis C virus genotype 6 patients, says researcher. DAAs do not increase risk of hepatic decompensation in HCV patients February 20, 2017By Mark L. FuerstResearchers say theirs is first national study with a large population to examine possible link. DAA therapy effective in advanced liver disease in real-world study February 20, 2017By Mark L. FuerstAll-oral sofosbuvir-based therapy proves a significant advance for hepatitis C virus patients. Researchers unveil optimal timing of HCV therapy in transplantation January 24, 2017By Mark FuerstA new study by Yale researchers reveals the optimal timing for hepatitis C virus therapy in patients eligible for a liver transplant. Oral DAA combination found effective in HCV patients January 24, 2017By Mark FuerstDirect-acting antiviral combination “represents an excellent treatment option” in some cases, says study’s senior author. DAAs aid treatment of hepatitis C patients with cancer December 01, 2016By Mark L. FuerstDirect-acting antiviral agents can be safely administered with chemotherapy in patients with hepatitis C virus, according to new research. DAA treatment restricted for Canadian hepatitis C patients December 01, 2016By Mark L. FuerstPatients with hepatitis C virus (HCV) in Canada are limited in their access to direct-acting antiviral agents, according to researchers.